Literature DB >> 24130011

Mapping the glycation sites in the neoglycoconjugate from hexasaccharide antigen of Vibrio cholerae, serotype Ogawa and the recombinant tetanus toxin C-fragment carrier.

Farid Jahouh1, Peng Xu, Willie F Vann, Pavol Kováč, Joseph H Banoub.   

Abstract

We report herein the glycation sites in a vaccine candidate for cholera formed by conjugation of the synthetic hexasaccharide fragment of the O-specific polysaccharide of Vibrio cholerae, serotype Ogawa, to the recombinant tetanus toxin C-fragment (rTT-Hc) carrier. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry analysis of the vaccine revealed that it is composed of a mixture of neoglycoconjugates with carbohydrate : protein ratios of 1.9 : 1, 3.0 : 1, 4.0 : 1, 4.9 : 1, 5.9 : 1, 6.9 : 1, 7.9 : 1 and 9.1 : 1. Liquid chromatography tandem mass spectrometry (LC-MS/MS) analysis of the tryptic and GluC V8 digests allowed identification of 12 glycation sites in the carbohydrate-protein neoglycoconjugate vaccine. The glycation sites are located exclusively on lysine (Lys) residues and are listed as follows: Lys 22, Lys 61, Lys 145, Lys 239, Lys 278, Lys 318, Lys 331, Lys 353, Lys 378, Lys 389, Lys 396 and Lys 437. Based on the 3-D representation of the rTT-Hc protein, all the glycation sites correspond to lysines located at the outer surface of the protein.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Keywords:  GluC V8 digestion; MALDI-TOF-MS; Trypsin digestion; nano-LC-ESI-QqTOF-MS/MS; neoglycoconjugate vaccine; recombinant tetanus toxin C-fragment (rTT-Hc)

Mesh:

Substances:

Year:  2013        PMID: 24130011      PMCID: PMC4155328          DOI: 10.1002/jms.3258

Source DB:  PubMed          Journal:  J Mass Spectrom        ISSN: 1076-5174            Impact factor:   1.982


  25 in total

1.  Conjugating low molecular mass carbohydrates to proteins. 1. Monitoring the progress of conjugation.

Authors:  Rina Saksena; Anatoly Chernyak; Alex Karavanov; Pavol Kovác
Journal:  Methods Enzymol       Date:  2003       Impact factor: 1.600

2.  A sweet T cell response.

Authors:  Rino Rappuoli; Ennio De Gregorio
Journal:  Nat Med       Date:  2011-12-06       Impact factor: 53.440

3.  The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling.

Authors:  Konstantin Arnold; Lorenza Bordoli; Jürgen Kopp; Torsten Schwede
Journal:  Bioinformatics       Date:  2005-11-13       Impact factor: 6.937

4.  Determination of the glycation sites of Bacillus anthracis neoglycoconjugate vaccine by MALDI-TOF/TOF-CID-MS/MS and LC-ESI-QqTOF-tandem mass spectrometry.

Authors:  Farid Jahouh; Shu-jie Hou; Pavol Kováč; Joseph H Banoub
Journal:  J Mass Spectrom       Date:  2011-10       Impact factor: 1.982

5.  Structure of tetanus toxin. II. Toxin binding to ganglioside.

Authors:  T B Helting; O Zwisler; H Wiegandt
Journal:  J Biol Chem       Date:  1977-01-10       Impact factor: 5.157

6.  Conjugating oligosaccharides to proteins by squaric acid diester chemistry: rapid monitoring of the progress of conjugation, and recovery of the unused ligand.

Authors:  A Chernyak; A Karavanov; Y Ogawa; P Kovác
Journal:  Carbohydr Res       Date:  2001-02-28       Impact factor: 2.104

7.  Preparations of antigens and immunoadsorbents corresponding to the Streptococcus group A cell-wall polysaccharide.

Authors:  F I Auzanneau; B M Pinto
Journal:  Bioorg Med Chem       Date:  1996-11       Impact factor: 3.641

8.  One-pot preparation of a series of glycoconjugates with predetermined antigen-carrier ratio from oligosaccharides that mimic the O-PS of Vibrio cholerae O:1, serotype Ogawa.

Authors:  Rina Saksena; Xingquan Ma; Pavol Kovác
Journal:  Carbohydr Res       Date:  2003-11-14       Impact factor: 2.104

9.  Multimeric bivalent immunogens from recombinant tetanus toxin HC fragment, synthetic hexasaccharides, and a glycopeptide adjuvant.

Authors:  Aileen F G Bongat; Rina Saksena; Roberto Adamo; Yukari Fujimoto; Zenyu Shiokawa; Dwight C Peterson; Koichi Fukase; Willie F Vann; Pavol Kovác
Journal:  Glycoconj J       Date:  2009-09-16       Impact factor: 2.916

10.  Neoglycoconjugates from synthetic tetra- and hexasaccharides that mimic the terminus of the O-PS of Vibrio cholerae O:1, serotype Inaba.

Authors:  Xingquan Ma; Rina Saksena; Anatoly Chernyak; Pavol Kovác
Journal:  Org Biomol Chem       Date:  2003-03-07       Impact factor: 3.876

View more
  5 in total

1.  Biotinylated N-Acetyllactosamine- and N,N-Diacetyllactosamine-Based Oligosaccharides as Novel Ligands for Human Galectin-3.

Authors:  Sophia Böcker; Lothar Elling
Journal:  Bioengineering (Basel)       Date:  2017-04-05

Review 2.  Meningococcal Vaccines: Current Status and Emerging Strategies.

Authors:  Pumtiwitt C McCarthy; Abeer Sharyan; Laleh Sheikhi Moghaddam
Journal:  Vaccines (Basel)       Date:  2018-02-25

Review 3.  Tetanus Toxin Fragment C: Structure, Drug Discovery Research and Production.

Authors:  Caroline Bayart; Angélique Mularoni; Nada Hemmani; Soumeya Kerachni; Joachim Jose; Patrice Gouet; Joseph Paladino; Marc Le Borgne
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-17

4.  Galectin Binding to Neo-Glycoproteins: LacDiNAc Conjugated BSA as Ligand for Human Galectin-3.

Authors:  Sophia Böcker; Dominic Laaf; Lothar Elling
Journal:  Biomolecules       Date:  2015-07-24

5.  Evaluation in mice of a conjugate vaccine for cholera made from Vibrio cholerae O1 (Ogawa) O-specific polysaccharide.

Authors:  Mohammad Murshid Alam; Megan Kelly Bufano; Peng Xu; Anuj Kalsy; Y Yu; Y Wu Freeman; Tania Sultana; Md Rasheduzzaman Rashu; Ishaan Desai; Grace Eckhoff; Daniel T Leung; Richelle C Charles; Regina C LaRocque; Jason B Harris; John D Clements; Stephen B Calderwood; Firdausi Qadri; W F Vann; Pavol Kováč; Edward T Ryan
Journal:  PLoS Negl Trop Dis       Date:  2014-02-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.